Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Phase 3
Active, not recruiting
NCT03765918
| Condition | Head and Neck Neoplasms |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Merck Sharp & Dohme LLC |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 714 participants |
|---|
| Interventions | Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2 |
|---|
| Start date | Dec 17, 2018 |
|---|
| Completion date | Jul 25, 2024 |
|---|
| Results posted | Aug 20, 2025 |
|---|
Summary
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
Event-free Survival (EFS)
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 51.8 Months |
|---|
| Standard of Care (SOC) | 30.4 Months |
|---|
| p-value | 0.00411 |
|---|
| Hazard Ratio (HR) | 0.73 (95% CI 0.58–0.92) |
|---|
EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 59.7 Months |
|---|
| Standard of Care (SOC) | 26.9 Months |
|---|
| p-value | 0.00217 |
|---|
| Hazard Ratio (HR) | 0.66 (95% CI 0.49–0.88) |
|---|
EFS in Participants With PD-L1 CPS ≥1
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 59.7 Months |
|---|
| Standard of Care (SOC) | 29.6 Months |
|---|
| p-value | 0.00140 |
|---|
| Hazard Ratio (HR) | 0.70 (95% CI 0.55–0.89) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.